changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
London, UK, 19 May 2015
BTG plc (LSE:BTG), the specialist healthcare company, today announces the launch of a sponsored Level 1 American Depositary Receipt (ADR) programme.
The ADR programme will be open for deposits from 9 a.m. (EST) today. The ADR's CUSIP is 05581D107, and the ADR ticker symbol is BTGYY. Each ADR represents one BTG ordinary share.
Andy Burrows, Vice President, Corporate and Investor Relations at BTG commented:
"Establishing a sponsored ADR offers U.S. investors a more structured platform on which to invest in our company. This step will raise our profile with the key U.S. investment base and supports our investor outreach programme."
J.P. Morgan will act as the depositary bank for the ADR programme. For market information on ADRs go to J.P. Morgan's web site: www.adr.com.
For further information please contact:
Andy Burrows, VP Corporate and Investor Relations
+44 (0)20 7575 1741; Mobile: +44 (0)7990 530605
Stuart Hunt, Investor Relations Manager
+44 (0)20 7575 1582; Mobile: +44 (0)7805 354134
Ben Atwell/Simon Conway
+44 (0)20 3727 1000
+44 (0)20 7134 5566
BTG is a growing international specialist healthcare company that is developing and commercialising products targeting acute care, cancer and vascular diseases. The company has diversified revenues from sales of its own marketed products and from royalties on partnered products, and is seeking to acquire new programmes and products to develop and market to specialist physicians. For further information about BTG please visit our website at www.btgplc.com.
Select CONTINUE to proceed to the BTG website or LEAVE to learn more at BSC.com